نبذة مختصرة : The clinical manifestations of variability in PLWH with SARS‐CoV‐2 acquired may be attributed to the use of ART drugs. Omicron breakthrough infection and reinfection in 27 PLWH treated with BIC/FTC/TAF and 51 PLWH treated with TDF/3TC/EFV were investigated, and humoral and cellular immunity after Omicron breakthrough infection were also compared. The results showed that Omicron breakthrough infection symptoms in BIC/FTC/TAF‐treated had a shorter duration, and BIC/FTC/TAF could further reduce the duration of symptoms when re‐infected. It was also found that the BA.5 specific IgG titers of BIC/FTC/TAF‐treated were significantly increased and increased with the extension of the duration of BIC/FTC/TAF. In cellular immunity, the use of BIC/FTC/TAF was also found to increase not only BA.5‐specific B lymphocytes and BA.5‐specific CD4 + T lymphocytes, but also total CD4 + T cells. In conclusion, compared to TDF/3TC/EFV, BIC/FTC/TAF can help PLWH shorten the duration of COVID − 19 symptoms, enhance SARS‐CoV‐2 specific humoral and cellular immune responses, help to expand the total CD4 + T cells increase in PLWH after Omicron infection and may be more beneficial for PLWH with high risk of infection in the context of COVID‐19 normalization.
Processing Request
No Comments.